Replimune Group (REPL)
(Delayed Data from NSDQ)
$9.86 USD
+0.13 (1.34%)
Updated Aug 14, 2024 04:00 PM ET
After-Market: $9.85 -0.01 (-0.10%) 7:58 PM ET
3-Hold of 5 3
D Value D Growth A Momentum D VGM
Brokerage Reports
0 items in cart
Replimune Group, Inc. [REPL]
Reports for Purchase
Showing records 81 - 100 ( 196 total )
Company: Replimune Group, Inc.
Industry: Medical - Biomedical and Genetics
Company: Replimune Group, Inc.
Industry: Medical - Biomedical and Genetics
Company: Replimune Group, Inc.
Industry: Medical - Biomedical and Genetics
MASTERKEY-265 Disappointing, but Read-Through to REPL Limited
Provider: WEDBUSH SECURITIES INC.
Analyst: DRISCOLL R
Company: Replimune Group, Inc.
Industry: Medical - Biomedical and Genetics
Company: Replimune Group, Inc.
Industry: Medical - Biomedical and Genetics
Company: Replimune Group, Inc.
Industry: Medical - Biomedical and Genetics
Company: Replimune Group, Inc.
Industry: Medical - Biomedical and Genetics
Fiscal Q1; Full Enrollment for Registration-Directed Programs Expected Mid:2022
Provider: WEDBUSH SECURITIES INC.
Analyst: DRISCOLL R
Company: Replimune Group, Inc.
Industry: Medical - Biomedical and Genetics
Company: Replimune Group, Inc.
Industry: Medical - Biomedical and Genetics
1Q21: The Next 12 Months Could be Transformational for the Platform
Provider: Roth Capital Partners, Inc.
Analyst: BUTLER T
Company: Replimune Group, Inc.
Industry: Medical - Biomedical and Genetics
Company: Replimune Group, Inc.
Industry: Medical - Biomedical and Genetics
Updated RP1 and RP2 Clinical Results; FY2021 Financials; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: BURNS R
Company: Replimune Group, Inc.
Industry: Medical - Biomedical and Genetics
Company: Replimune Group, Inc.
Industry: Medical - Biomedical and Genetics
Company: Replimune Group, Inc.
Industry: Medical - Biomedical and Genetics
Positive Data Updates for RP1 and RP2; Liver Mets Program Announced
Provider: WEDBUSH SECURITIES INC.
Analyst: DRISCOLL R
Company: Replimune Group, Inc.
Industry: Medical - Biomedical and Genetics
Fiscal Q4 Financials; Clinical Updates Ahead at Investor Event
Provider: WEDBUSH SECURITIES INC.
Analyst: DRISCOLL R
Company: Replimune Group, Inc.
Industry: Medical - Biomedical and Genetics
Company: Replimune Group, Inc.
Industry: Medical - Biomedical and Genetics
FY2021 Results. Important to Watch Clinical Updates in June.
Provider: Roth Capital Partners, Inc.
Analyst: BUTLER T
Company: Replimune Group, Inc.
Industry: Medical - Biomedical and Genetics
Positive Regulatory Updates for RP1 in CSCC and PD-1-Refractory Melanoma
Provider: WEDBUSH SECURITIES INC.
Analyst: Research Department